The Provincial Pharmaceutical Industry Science, Technology, and Health Innovation Consortium held a symposium at our company.

To better explore experiences in collaborative innovation within the pharmaceutical industry, accelerate the pace of transferring scientific and technological breakthroughs, speed up the dissemination of new technologies and methodologies, help enterprises address their challenges and meet their needs, and ultimately enhance their market competitiveness, the provincial Pharmaceutical Industry Science & Technology Innovation Health Consortium Symposium was held at our company on the afternoon of May 14.

Representatives from the Provincial Development and Reform Commission, Changchun University of Traditional Chinese Medicine, Pharmaceutical Consortium Office, Northeast Normal University, Jilin University, Provincial Academy of Traditional Chinese Medicine, CAS Changchun Branch, and Jilin Provincial Institute of Drug Control; leaders, experts, and scholars from the Municipal Party Committee and Government, as well as industrial and information technology, science and technology, and regulatory departments of Liaoyuan’s two districts and two counties; over 40 representatives from the 21 member units of the Liaoyuan Pharmaceutical Consortium, along with company Chairman Duan Chengjun and General Manager Xie Wenbo, attended the meeting.

The meeting was chaired by Wang Shiming, a researcher from the Municipal Development and Reform Commission. First to speak was Director Zhai Yandong from the Provincial Development and Reform Commission. Yue Bin, Deputy Secretary-General of the Municipal Government Office, then delivered a detailed report on Liaoyuan City's pharmaceutical and healthcare industry. Following him, Qiu, President of Changchun University of Traditional Chinese Medicine and also the head of the expert panel, took the floor. Finally, Xie Wenbo, General Manager of Bodaweiyue Company, presented an overview of his firm's progress in developing the pharmaceutical and healthcare sector. Mr. Xie's presentation received widespread recognition from the attending leaders, experts, and peers. Afterward, participating companies engaged in lively interactions with the academic specialists, who patiently addressed each question raised by the audience.

As the chairperson unit of the Jilin Province Chemical Pharmaceutical Industry Technology Innovation Strategic Alliance—Jilin Boda Weiye Pharmaceutical Co., Ltd.—we are firmly committed to a strategy centered on "focusing on projects, optimizing the environment, and ensuring implementation," driving the research and development and production of groundbreaking, innovative drugs. Our comprehensive business strategy spans the entire spectrum of R&D, manufacturing, and sales, with a particular emphasis on cardiovascular, digestive, anti-cancer, and neuropsychiatric medications. Seizing the favorable opportunity presented by the new wave of revitalization in Northeast China and the ongoing development of the "Changliaomei Tongbai Dun Pharmaceutical and Health Corridor," we are poised to further accelerate the growth of the pharmaceutical and health industry cluster, opening up vast potential for robust and promising future prospects.